Related Experiment Video
Updated: Nov 21, 2025

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Liquid CO2 Formulated Mesoporous Silica Nanoparticles for pH-Responsive Oral Delivery of Meropenem
Aun Raza1,2, Fekade Bruck Sime1,2, Peter J Cabot1
1School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Abstract:
Meropenem (MER) is an effective broad-spectrum antibiotic currently only available in the parenteral form requiring frequent drug preparation and administration due to its extremely poor stability. The unavailability of oral Meropenem is primarily due to its ultrapoor handling and processing stability, hydrophilic nature that inhibits the passive diffusion across the gastrointestinal (GI) epithelium, degradation in the harsh gastric environment, and GI expulsion through enterocyte efflux glycoproteins. In this regard, we have developed an oral drug delivery system that confines MER into mesoporous silica nanoparticles (MSNs i.e, MCM-41 ∼141 nm) using a novel liquid carbon dioxide (CO2) method. MER was efficiently encapsulated within pristine, phosphonate (negatively charged MSN), and amine (positively charged MSN) modified MSNs with loading capacity ranging between 25 wt % and 31 wt %. Next, the MER-MCM-NH2 particles were electrostatically coated with Eudragit S100 enteric polymer that protected MER against gastric pH (pH 1.9) and enabled site-specific delivery in the small intestine (pH 6.8). Cellular uptake results in RAW 264.7 macrophage, Caco-2, and LS174T cells confirming the efficient cellular uptake of nanoparticles in all three cell lines. More importantly, the bidirectional transport (absorptive and secretory) of MER across Caco-2 monolayer was significantly improved for both MSN-based formulations, particularly MSNs coated with a polymer (Eud-MER-MCM-NH2) where permeability was significantly enhanced (∼2.4-fold) for absorptive transport and significantly reduced (∼1.8-fold) for secretory transport. Finally, in vitro antibacterial activity [minimum inhibitory concentration (MIC)] and time-kill assay against S. aureus and P. aeruginosa showed that drug-loaded nanoparticles were able to retain antibacterial activity comparable to that of free MER in a solution at equivalent dose. Thus, Eudragit-coated silica nanoparticles could offer a promising and novel solution for oral delivery of Meropenem and other such drugs.
Insights
Researchers developed an oral drug delivery system using mesoporous silica nanoparticles (MSNs) to improve meropenem (MER) stability and absorption. This novel approach enhances oral meropenem delivery, overcoming limitations of the current injectable form.
Area of Science:
- Nanotechnology
- Pharmaceutical Sciences
- Drug Delivery Systems
Background:
- Meropenem (MER) is a vital broad-spectrum antibiotic, but its parenteral administration is limited by poor stability and handling.
- Existing challenges for oral MER include poor stability, hydrophilic nature hindering GI absorption, gastric degradation, and efflux transporter expulsion.
Purpose of the Study:
- To develop a novel oral drug delivery system for meropenem (MER) using mesoporous silica nanoparticles (MSNs).
- To enhance the stability, gastrointestinal permeability, and oral bioavailability of MER.
Main Methods:
- Encapsulation of MER into pristine, phosphonate, and amine-modified MSNs (MCM-41) via a liquid CO2 method.
- Electrostatic coating of MER-loaded MSNs (MER-MCM-NH2) with Eudragit S100 enteric polymer for targeted intestinal delivery.
- Evaluation of cellular uptake in RAW 264.7, Caco-2, and LS174T cells.
- Assessment of bidirectional transport across Caco-2 monolayers and in vitro antibacterial activity against S. aureus and P. aeruginosa.
Main Results:
- Efficient MER encapsulation in MSNs with 25-31 wt% loading capacity.
- Eudragit S100 coating protected MER from gastric acidity and enabled intestinal release.
- Significantly enhanced absorptive transport (∼2.4-fold) and reduced secretory transport (∼1.8-fold) of MER across Caco-2 monolayers.
- Drug-loaded nanoparticles retained potent in vitro antibacterial activity comparable to free MER.
Conclusions:
- Eudragit-coated mesoporous silica nanoparticles represent a promising strategy for the oral delivery of meropenem.
- This nanotechnology-based approach effectively overcomes the limitations of parenteral administration and enhances MER's therapeutic potential.

